HALAVEN (eribulin mesylate) for Refractory Metastatic Breast Cancer

1 / 1
Share this content:

This slideshow reviews drug information for HALAVEN (eribulin mesylate), indicated for refractory metastatic breast cancer.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 10: Clinical Pharmacology
Slide 14: Warnings and Precautions
Slide 16: Clinical Safety and Efficacy
Slide 22: Drug Storage and Supply
Slide 24: References

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs